137 related articles for article (PubMed ID: 38592948)
1. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
Pervanidis KA; D'Angelo GD; Weisner J; Brandherm S; Rauh D
J Med Chem; 2024 Apr; 67(8):6052-6063. PubMed ID: 38592948
[TBL] [Abstract][Full Text] [Related]
2. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
3. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
4. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Yaroschak M; Bilodeau MT; Layton ME
Curr Top Med Chem; 2007; 7(14):1349-63. PubMed ID: 17692025
[TBL] [Abstract][Full Text] [Related]
6. ATP-competitive and allosteric inhibitors induce differential conformational changes at the autoinhibitory interface of Akt1.
Shaw AL; Parson MAH; Truebestein L; Jenkins ML; Leonard TA; Burke JE
Structure; 2023 Mar; 31(3):343-354.e3. PubMed ID: 36758543
[TBL] [Abstract][Full Text] [Related]
7. Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors.
Wang Z; Ran T; Xu F; Wen C; Song S; Zhou Y; Chen H; Lu X
Chem Commun (Camb); 2021 Oct; 57(81):10588-10591. PubMed ID: 34560776
[TBL] [Abstract][Full Text] [Related]
8. "The emerging role of capivasertib in breast cancer".
Andrikopoulou A; Chatzinikolaou S; Panourgias E; Kaparelou M; Liontos M; Dimopoulos MA; Zagouri F
Breast; 2022 Jun; 63():157-167. PubMed ID: 35398754
[TBL] [Abstract][Full Text] [Related]
9. Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER
Robertson JFR; Coleman RE; Cheung KL; Evans A; Holcombe C; Skene A; Rea D; Ahmed S; Jahan A; Horgan K; Rauchhaus P; Littleford R; Cheung SYA; Cullberg M; de Bruin EC; Koulai L; Lindemann JPO; Pass M; Rugman P; Schiavon G; Deb R; Finlay P; Foxley A; Gee JMW
Clin Cancer Res; 2020 Apr; 26(7):1574-1585. PubMed ID: 31836609
[TBL] [Abstract][Full Text] [Related]
10. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
11. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrrolopyrimidine inhibitors of Akt.
Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
[TBL] [Abstract][Full Text] [Related]
14. Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity.
Liu Y; Zhang Z; Ran F; Guo K; Chen X; Zhao G
Bioorg Chem; 2020 Apr; 97():103671. PubMed ID: 32120074
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Yap TA; Walton MI; Hunter LJ; Valenti M; de Haven Brandon A; Eve PD; Ruddle R; Heaton SP; Henley A; Pickard L; Vijayaraghavan G; Caldwell JJ; Thompson NT; Aherne W; Raynaud FI; Eccles SA; Workman P; Collins I; Garrett MD
Mol Cancer Ther; 2011 Feb; 10(2):360-71. PubMed ID: 21191045
[TBL] [Abstract][Full Text] [Related]
16. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
[TBL] [Abstract][Full Text] [Related]
17. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).
McHardy T; Caldwell JJ; Cheung KM; Hunter LJ; Taylor K; Rowlands M; Ruddle R; Henley A; de Haven Brandon A; Valenti M; Davies TG; Fazal L; Seavers L; Raynaud FI; Eccles SA; Aherne GW; Garrett MD; Collins I
J Med Chem; 2010 Mar; 53(5):2239-49. PubMed ID: 20151677
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
[TBL] [Abstract][Full Text] [Related]
20. Covalent-Allosteric Kinase Inhibitors.
Weisner J; Gontla R; van der Westhuizen L; Oeck S; Ketzer J; Janning P; Richters A; Mühlenberg T; Fang Z; Taher A; Jendrossek V; Pelly SC; Bauer S; van Otterlo WA; Rauh D
Angew Chem Int Ed Engl; 2015 Aug; 54(35):10313-6. PubMed ID: 26110718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]